Scholar Rock (NASDAQ:SRRK) has announced encouraging preclinical results for its myostatin inhibitor, SRK-439, during the American Diabetes Association's 84th Scientific Sessions.
The study indicates that SRK-439 can help preserve lean mass and mitigate fat mass rebound following the discontinuation of GLP-1 receptor agonist treatment in mice.
“These new preclinical data provide compelling evidence that SRK-439 contributed to lean muscle preservation during GLP-1 RA-induced weight loss and attenuated fat mass rebound following discontinuation of semaglutide,” said Mo Qatanani, PhD, Chief Scientific Officer at Scholar Rock.
Meanwhile, the Phase 2 EMBRAZE proof-of-concept trial to assess the safety and efficacy of apitegromab in obese individuals has begun, with the first participants already dosed.